Argenx said Thursday that its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren’s disease, a chronic autoimmune disorder.
It’s an unusual setback for Argenx, which has racked up a series of wins in autoimmune disorders en route to becoming one of the world’s largest biotechs by market cap.
Argenx’s stock slipped 13% Thursday morning.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source: www.statnews.com
